Exact Sciences Co. (NASDAQ:EXAS) Holdings Lifted by Thompson Investment Management Inc.

Thompson Investment Management Inc. grew its holdings in shares of Exact Sciences Co. (NASDAQ:EXAS) by 17.8% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 241,774 shares of the medical research company’s stock after acquiring an additional 36,505 shares during the quarter. Exact Sciences accounts for approximately 2.0% of Thompson Investment Management Inc.’s holdings, making the stock its 6th biggest holding. Thompson Investment Management Inc. owned approximately 0.13% of Exact Sciences worth $13,585,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Geode Capital Management LLC increased its stake in shares of Exact Sciences by 0.3% in the third quarter. Geode Capital Management LLC now owns 3,105,970 shares of the medical research company’s stock worth $211,104,000 after buying an additional 7,873 shares during the period. Champlain Investment Partners LLC increased its position in Exact Sciences by 10.9% during the 3rd quarter. Champlain Investment Partners LLC now owns 2,494,480 shares of the medical research company’s stock valued at $169,924,000 after purchasing an additional 245,980 shares during the period. Bellevue Group AG increased its position in Exact Sciences by 25.1% during the 3rd quarter. Bellevue Group AG now owns 1,449,465 shares of the medical research company’s stock valued at $98,738,000 after purchasing an additional 290,585 shares during the period. Charles Schwab Investment Management Inc. increased its position in Exact Sciences by 3.6% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,292,090 shares of the medical research company’s stock valued at $88,017,000 after purchasing an additional 45,015 shares during the period. Finally, Groupama Asset Managment purchased a new position in Exact Sciences during the 3rd quarter valued at $821,000. 88.82% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Exact Sciences news, CEO Kevin T. Conroy bought 19,500 shares of the firm’s stock in a transaction on Wednesday, November 13th. The stock was acquired at an average price of $51.35 per share, with a total value of $1,001,325.00. Following the transaction, the chief executive officer now owns 1,074,191 shares in the company, valued at $55,159,707.85. This represents a 1.85 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. 1.36% of the stock is owned by insiders.

Exact Sciences Price Performance

Shares of NASDAQ:EXAS opened at $53.53 on Friday. Exact Sciences Co. has a fifty-two week low of $40.62 and a fifty-two week high of $79.62. The business has a 50-day simple moving average of $57.31 and a two-hundred day simple moving average of $60.04. The company has a debt-to-equity ratio of 0.72, a quick ratio of 1.93 and a current ratio of 2.12. The firm has a market cap of $9.91 billion, a price-to-earnings ratio of -45.75 and a beta of 1.24.

Analyst Upgrades and Downgrades

EXAS has been the topic of a number of research analyst reports. TD Cowen boosted their price objective on shares of Exact Sciences from $82.00 to $86.00 and gave the company a “buy” rating in a research report on Tuesday, November 26th. Sanford C. Bernstein boosted their target price on shares of Exact Sciences from $75.00 to $90.00 and gave the company an “outperform” rating in a report on Wednesday, October 30th. BTIG Research boosted their target price on shares of Exact Sciences from $65.00 to $75.00 and gave the company a “buy” rating in a report on Tuesday, November 26th. Evercore ISI dropped their target price on shares of Exact Sciences from $80.00 to $60.00 and set an “outperform” rating on the stock in a report on Wednesday, November 6th. Finally, Piper Sandler dropped their target price on shares of Exact Sciences from $85.00 to $75.00 and set an “overweight” rating on the stock in a report on Monday, November 11th. One investment analyst has rated the stock with a hold rating and eighteen have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $72.76.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.